MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
1.210
-0.020
-1.63%
After Hours: 1.216 +0.006 +0.50% 19:52 07/17 EDT
OPEN
1.280
PREV CLOSE
1.230
HIGH
1.280
LOW
1.180
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
1.710
52 WEEK LOW
0.8800
MARKET CAP
139.45M
P/E (TTM)
-4.3061
1D
5D
1M
3M
1Y
5Y
1D
Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 4d ago
H.C. Wainwright Remains a Buy on Cardiol Therapeutics (CRDL)
TipRanks · 4d ago
Cardiol Therapeutics nears full enrollment for Phase III MAVERIC trial of CardiolRx in recurrent pericarditis
PUBT · 4d ago
Cardiol Therapeutics’ CardiolRx featured in Phase 2 pericarditis published trial
TipRanks · 4d ago
Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association
Benzinga · 4d ago
Cardiol Therapeutics says Phase II recurrent pericarditis data for CardiolRx published in JAHA
PUBT · 4d ago
Stocks in play: Cardiol Therapeutics Inc.
Barchart · 4d ago
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.